The purpose of the trial is to examine the effectiveness of Zyflo at reducing the length of a hospital stay for adults who are hospitalized for a chronic obstructive pulmonary disease (COPD) exacerbation.
The clinical trial is being sponsored and funded by the National Heart, Lung and Blood Institute, part of the National Institutes of Health (NIH), and is being conducted by the COPD Clinical Research Network.
Enrollment of 520 patients is planned for 19 inpatient hospitals at 10 academic centers in the US. Eligible patients should have been admitted to the hospital with acute exacerbations of COPD, have at least 10 pack years of smoking and have a forced expiratory volume in one second of less than 60% of predicted level. Patients will be randomized to receive either oral placebo or Zyflo (zileuton) for 14 days.